Why Fisher & Paykel Healthcare (NZSE:FPH) Is Back In The Spotlight
Why Fisher & Paykel Healthcare guidance matters now
Fisher & Paykel Healthcare (NZSE:FPH) drew investor attention on 20 August 2026 after updating its outlook for the 2027 financial year, with higher full year earnings guidance and fresh expectations for the first half.
See our latest analysis for Fisher & Paykel Healthcare.
The guidance upgrade on 20 August 2026 comes after a strong run in Fisher & Paykel Healthcare shares, with a 12.18% 1 month share price return, a 20.39% 3 month share price return and a 19.99% 1 year total shareholder return suggesting positive momentum around its earnings outlook.
If this kind of momentum has your attention, it could be a useful time to see which other healthcare companies are using AI in interesting ways through the 131 healthcare AI stocks
After that run and the upgraded 2027 guidance, Fisher & Paykel Healthcare now asks a simple question of you. Is it worth paying up at today’s price, or does waiting for a cheaper entry look more sensible once you check the valuation?
Most Popular Narrative: 11% Overvalued
Fisher & Paykel Healthcare last closed at NZ$44.22, compared with the most widely followed narrative fair value of NZ$39.75. That gap frames how investors might read the upgraded 2027 guidance.
Global demographic shifts, specifically an aging population and increasing incidence of chronic respiratory conditions, are creating sustained demand for respiratory care devices and therapies. This is expected to underpin growth in addressable markets and support top-line revenue expansion for Fisher & Paykel Healthcare.
Want to see what sits behind that growth story? The narrative focuses on rising revenue, higher margins and a richer earnings multiple. The exact mix may surprise you.
Result: Fair Value of NZ$39.75 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to weigh risks such as tighter hospital budgets and higher tariffs on New Zealand exports, which could pressure Fisher & Paykel Healthcare margins and demand.
Find out about the key risks to this Fisher & Paykel Healthcare narrative.
Next Steps
With investors already optimistic about Fisher & Paykel Healthcare, it helps to move quickly and test that sentiment against the numbers yourself. To see how those rewards stack up in detail, review the 2 key rewards
Looking for more investment ideas beyond Fisher & Paykel Healthcare?
If Fisher & Paykel Healthcare has sharpened your focus, do not stop there. Use the Simply Wall St Screener to spot fresh opportunities before other investors catch on.
- Target potential value opportunities by scanning for companies that combine quality fundamentals with attractive pricing through the 269 high quality undervalued stocks.
- Strengthen your income focus by reviewing companies with higher yields and resilient payout histories in the 423 dividend fortresses.
- Prioritise resilience by filtering for companies with lower risk profiles and sturdier financial characteristics using the 290 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com